Search

Serdexmethylphenidate

[A230698, A230708] Serdexmethylphenidate is a prodrug of the CNS stimulant [dexmethylphenidate], a common first-line treatment for ADHD, that is combined with [dexmethylphenidate] to provide extended plasma

Aminohippuric acid

Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]

Atoltivimab

[A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection. … Ebola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%.

Cerliponase alfa

[L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency.

Taurocholic acid

Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.

Sofosbuvir

substrate for NS5B (non-structural protein 5B) [synthesis]. … NS5B, an RNA-dependent RNA polymerase, is essential for the transcription of Hepatitis C viral RNA and for its high replicative rate and genetic diversity [A19594].

Foreskin fibroblast (neonatal)

Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997. … The device is available for commercial distribution in Australia, Canada, Finland, France, Hong Kong, Ireland, The Netherlands, New Zealand, Singapore, and The United Kingdom [L2418].

Mogamulizumab

[L4168] It was approved for the same indications in Canada in June 2022. … Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF

Maribavir

Maribavir was approved by the FDA in November 2021, under the name Livtencity (Takeda), for the treatment of resistant CMV infections in post-transplant patients. … [L39322] Most standard CMV therapies, such as [ganciclovir] or [foscarnet], target CMV DNA polymerase - while generally effective, these medications tend to promote the development of CMV resistance to

VL-2397